This article provides examples of how AI is helping to shape drug discovery, from drug design through to clinical trials.

The $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other ...

Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop ...

By combining diverse datasets and powerful analytical and modeling tools, drug developers are finding more potential ...

The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...

The AI in cancer care market is set to grow from $2.2 billion in 2024 to $6.3 billion by 2029, driven by advancements in drug ...

GSK took center stage last month, forming standout partnerships and alliances across multiple therapeutic areas.

Selected preclinical small molecule candidates will now be tested through the Quris-AI platform prior to initiating clinical trials. This follows a successful two-year validation study with Merck KGaA ...

In 2023, the global breast cancer drug market is projected to be worth USD 10,733.1 million.  Between 2023 and 2033, the demand for breast cancer drugs is expected to expand at a CAGR of 1.1%, ...

In recent years, generative AI (GenAI) has become a prominent topic of discussion in life sciences. However, I often hear from my life science clients about the need for more clarity around its ...

Self-driving cars, specialized robots for medical procedures or factory work, and general-purpose robots as home assistants ...